An aqueous pharmaceutical formulation having an insulin analog, zinc 0.001~0.2mg / ml, preservatives 0.1~5.0mg / ml, and the present invention, etc. The 5.0~100mg / ml less than or equal to 5, the pH of pharmaceutical formulation and comprise a tonicity agent. Furthermore, their ...
Conventional slow-acting insulin preparations for subcutaneous injection, e.g., suspensions of the complex with protamine and/or zinc, were reformulated as... R Vanbever,A Ben-Jebria,JD Mintzes,... - 《Drug Development Research》 被引量: 15发表: 2015年 New insulins and insulin therapy cont...
ACTA CIRÚRGICA BRASILEIRA ORIGINAL ARTICLE Experimental Surgery A non-inferiority study to compare daily fast-acting insulin versus twice a week slow-acting insulin–moderate diabetes model1 Cristina Pires CamargoI , Rafael Hori Nagamine WeschenfelderII , Guilherme Moreira da...
The invention relates to aqueous pharmaceutical formulations having an insulin analog, said formulations comprising 0.001 to 0.2 mg/ml of zinc, 0.1 to 5.0 mg/ml of a preservative, and 5.0 to 100 mg/ml of an isotonic agent, and the pH value of which is 5 or less. The invention further ...
Rapid- and slow-acting insulins help control diabetesIf the united states' healthcare trend continues on its current course, in 20 years the number of people with diabetes will more than double to 50 million. This dismaying prediction comes from a new report from the Yale Schools of Public ...
Also, their preparation, their use for treating diabetes mellitus and a Medicine to treat diabetes mellitus.Claim 1: aqueous Pharmaceutical formulations comprising an insulin Analogue to formula (1) where A0 is Lys or Arg; A5 is ASP, GLN or Glu, ASP Glu or GLN is A15 and A18 is ASP, ...
On page 559, right column, 3rd paragraph, the first sentence should read:''In this work, two types of insulin were considered: lispro (Eli Lilly and Company, Indianapolis, IN) as the rapid-acting insulin and glargine (Lantus®, sanofi-aventis, Bridgewater, NJ) as the slow-actingF ...
insulin, thus noticeably increasing drug acceptance. further, the present invention relates to the administration of a pharmaceutical composition for reducing pancreatic beta cell side effects in diabetic patients, including a slow acting insulin analogue conjugate and a slow acting insulinotropic peptide ...
They were prescribed slow-acting metformin at a daily dose of 500 mg for six months. Treatment with metformin in euthyroid patients with uninodular thyroid disease and insulin resistance reduces TSH levels, increases FT4 and FT3 values, and decreases thyroid and nodule volumes. These data suggest ...
Statistical analyses were performed on all data sets using a basic Student’s paired, two-sided t-test that compared pre- and post-treatment measurements with each patient acting as their own control. With a power of 80%, a confidence level of 95%, an alpha-value (possibility of Type I ...